Literature DB >> 21480135

Prognostic factors for survival in patients with thymic epithelial tumors.

S Demirci1, K Turhan, N Ozsan, D Yalman, A Cakan, G Cok, U Cagirici, S Ozkok.   

Abstract

BACKGROUND: Aim of the study was to identify and evaluate the prognostic efficacy of standard clinicopathological factors of thymic epithelial tumors (TETs) for treatment-related outcomes.
MATERIALS AND METHODS: All patients treated between 1993-2008 at Ege University Faculty of Medicine Departments of Radiation Oncology and Thoracic Surgery were reviewed retrospectively.
RESULTS: Forty-seven patients with a median age of 51 (range: 24-72) were identified. Complete resection was performed in 23 (51.1%), incomplete resection with microscopic residues in 17 (37.8%), subtotal resection with gross residues in 2 (4.4%) and biopsy in 5 (11.1%) patients. Radiotherapy was administered to 39 (83%) patients. Median follow-up duration was 51 months (range: 3-168 months). Five-year local recurrence-free survival (LRFS), disease-free survival (DFS), and overall survival (OS) rates were 93%, 90% and 85% for thymoma and 80%, 66% and 72% for thymic carcinoma patients, respectively. In multivariate analysis, the extent of resection was the only significant prognostic factor for OS (P = 0.001).
CONCLUSIONS: The most important prognostic factor for overall survival was the extent of resection. Further studies with larger numbers of patients are required to confirm the prognostic factors and to obtain a better understanding of the biological behavior of TETs. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2011        PMID: 21480135     DOI: 10.1055/s-0030-1250657

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  7 in total

1.  The role of adjuvant chemotherapy following resection of early stage thymoma.

Authors:  Masatsugu Hamaji
Journal:  Ann Cardiothorac Surg       Date:  2016-01

2.  Intra-Thoracic Chemo-Hyperthermia for pleural recurrence of thymomas.

Authors:  Jean-Michel Maury; Gabrielle Drevet; Francois Tronc; Nicolas Girard
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

3.  Editorial: pleural recurrence of thymoma-what is the value of intra-thoracic chemo-hyperthermia?

Authors:  Anja C Roden; Julian R Molina
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

4.  Treatment and prognosis of Masaoka stage 3 thymic carcinoma: a retrospective study of 32 cases.

Authors:  Yan Sun; Jinshi Liu; Xinmin Yu
Journal:  Onco Targets Ther       Date:  2015-04-06       Impact factor: 4.147

5.  Does size affect the prognosis of resectable thymoma beyond the eighth edition TNM?

Authors:  Yen-Chiang Tseng; Han-Shui Hsu; Yi-Hsuan Lin; Yen-Han Tseng; Chih-Wen Shu; Yih-Gang Goan; Ching-Jiunn Tseng
Journal:  Thorac Cancer       Date:  2021-12-20       Impact factor: 3.500

6.  Treatment and prognosis of type B2 thymoma.

Authors:  Zhengbo Song; Xiangyu Jin; Yiping Zhang
Journal:  World J Surg Oncol       Date:  2014-09-20       Impact factor: 2.754

7.  Impact of Definitive Radiotherapy and Surgical Debulking on Treatment Outcome and Prognosis for Locally Advanced Masaoka-Koga stage III Thymoma.

Authors:  Chengcheng Fan; Hong Ge; Shaokai Zhang; Wenqun Xing; Ke Ye; Yan Zheng; Haibo Sun; Hao Wang; Xiaoli Zheng; Ruiyun Zhang; Meiling Liu
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.